| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.04. | Newron Pharmaceuticals - Pivotal evenamide trial looms | 434 | Edison Investment Research | Newron Pharmaceuticals has published its FY24 results, reflecting a rewarding period for its lead clinical candidate, evenamide, which is being developed for treatment-resistant schizophrenia (TRS).... ► Artikel lesen | |
| 03.04. | OSE Immunotherapeutics - Primed for value appreciation | 249 | Edison Investment Research | OSE Immunotherapeutics is a clinical-stage immuno-oncology and immuno-inflammation company, with a pipeline spanning all stages of development. The company recently reported its FY24 results, reflecting... ► Artikel lesen | |
| 03.04. | Isofol (ST: ISOFOL) to receive financing to support Phase II & III trials of arfolitixorin in Japan | 211 | Edison Investment Research | Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the... ► Artikel lesen | |
| 03.04. | Moonpig - FY25 update shows continued cash generation | 228 | Edison Investment Research | Moonpig's trading statement for FY25 (to end April) shows that the year looks set to finish in line or slightly better than expected. This is despite a challenging consumer confidence and geopolitical... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 2.594 |
| EVOTEC | 2.177 |
| NOVO NORDISK | 1.658 |
| RHEINMETALL | 1.089 |
| TESLA | 1.031 |
| RENK GROUP | 1.028 |
| BYD | 828 |
| TUI | 810 |
| DEUTZ | 794 |
| STEYR MOTORS | 785 |
| SIEMENS ENERGY | 692 |
| UNITEDHEALTH | 620 |
| PLUG POWER | 583 |
| NEL | 567 |
| APPLE | 505 |
| VOLKSWAGEN | 483 |
| PUMA | 482 |
| BASF | 447 |
| ALMONTY | 439 |
| ELI LILLY | 424 |
| DEUTSCHE BANK | 423 |
| BAYER | 420 |
| MERCEDES-BENZ | 401 |
| TSMC | 396 |
| XIAOMI | 385 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
